Clinical Trials Browser

Phase 1/2 × Paraganglioma × CNS × Clear all

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1/2 Recruiting

Paraganglioma, Pheochromocytoma

NCT04187404 2026-01-30

Spencer

Phase 1/2 Terminated

70 enrolled 20 charts

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Phase 1/2 Recruiting

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT02177773 2019-11-12

DOTA-TOC

Phase 1/2 Terminated

300 enrolled 5 charts

CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Phase 1/2 Completed

24 enrolled 8 charts

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors